Treatment options for Graves' orbitopathy

Bibliography

• Bahn RS. Graves' ophthalmopathy. N Engl J Med 2010;362:726-38
   PubMed Web of Science ®Google Scholar
• Bartalena L, Tanda ML. Graves' ophthalmopathy. N Engl J Med 2009;360:994-1001
   PubMed Web of Science ®Google Scholar
• Wiersinga WM, Perros P, Kahaly GJ, Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 2006;155:387-9
   PubMed Web of Science ®Google Scholar
• Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 2000;21:168-99
   PubMed Web of Science ®Google Scholar
• Bartalena L, Baldeschi L, Dickinson AJ, Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of Graves' Orbitopathy. Eur J Endocrinol 2008;158:273-85
   PubMed Web of Science ®Google Scholar
• Marcocci C, Pinchera A. Thyroid treatment. In: Wiersinga WM, Kahaly GJ, editors. Graves' Orbitopathy. A Multidisciplinary Approach – Questions and Answers. 2nd, revised version, pp 100-10 Karger; Basel: 2010
   Google Scholar
• Prummel MF, Wiersinga WM, Mourits MP, Amelioration of eye changes of Graves' ophthalmopathy by achieving euthyrodism. Acta Endocrinol (Copenh) 1989;121(Suppl 2):185-9
   PubMedGoogle Scholar
• Bartalena L. The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab 2011;96:592-9
   PubMed Web of Science ®Google Scholar
• Wiersinga WM. Preventing Graves' ophthalmopathy. N Engl J Med 1998;338:121-2
   PubMed Web of Science ®Google Scholar
• Marcocci C, Bartalena L, Pinchera A. Ablative or non-ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy. J Endocrinol Invest 1998;21:468-71
   PubMed Web of Science ®Google Scholar
• Rivkees SA, Dinauer C. An optimal treatment for pediatric Graves' disease is radioiodine. J Clin Endocrinol Metab 2007;92:797-800
   PubMed Web of Science ®Google Scholar
• Laurberg P, Wallin G, Tallstedt L, TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 2008;158:69-75
   PubMed Web of Science ®Google Scholar
• Vitti P, Rago T, Chiovato L, Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 1997;7:369-75
   PubMed Web of Science ®Google Scholar
• Acharya SH, Avenell A, Philip S, Radioiodine therapy (RAI) for Graves' disease (DG) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol (Oxf) 2008;69:943-50
   PubMed Web of Science ®Google Scholar
• Bartalena L, Marcocci C, Bogazzi F, Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998;338:73-8
   PubMed Web of Science ®Google Scholar
• Traisk F, Tallstedt L, Abraham-Nordling M, Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 2009;94:3700-7
   PubMed Web of Science ®Google Scholar
• Lazarus JH, Bartalena L, Marcocci C, Glucocorticoid administration for Graves' hyperthyroidism treated by radioiodine. A questionnaire survey among members of the European Thyroid Association. J Endocrinol Invest 2010;33:409-13
   PubMed Web of Science ®Google Scholar
• Lai A, Sassi L, Compri E, Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves' orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab 2010;95:1333-7
   PubMed Web of Science ®Google Scholar
• Perros P, Kendall-Taylor P, Neoh C, A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves' ophthalmopathy. J Clin Endocrinol Metab 2005;90:5321-3
   PubMed Web of Science ®Google Scholar
• Vannucchi G, Campi I, Covelli D, Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis. J Clin Endocrinol Metab 2009;94:3381-6
   PubMed Web of Science ®Google Scholar
• Stan MN, Bahn RS. Risk factors for development or deterioration of Graves' ophthalmopathy. Thyroid 2010;20:777-83
   PubMed Web of Science ®Google Scholar
• Marcocci C, Bruno-Bossio G, Manetti L, The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study. Clin Endocrinol (Oxf) 1999;51:503-8
   PubMed Web of Science ®Google Scholar
• Tallstedt L, Lundell G, Blomgren H. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur J Endocrinol 1994;130:494-7
   PubMed Web of Science ®Google Scholar
• Catz B, Perzik SL. Total thyroidectomy in the management of thyrotoxic and euthyroid Graves' disease. Am J Surg 1969;118:434-8
   PubMed Web of Science ®Google Scholar
• Menconi F, Marino M, Pinchera A, Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab 2007;92:1653-8
   PubMed Web of Science ®Google Scholar
• Leo M, Marcocci C, Pinchera A, Outcome of Graves' orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial. J Clin Endocrinol Metab 2012;97:E44-8
   PubMed Web of Science ®Google Scholar
• Dickinson AJ. Clinical manifestations. In: Wiersinga WM, Kahaly GJ, editors. Graves' Orbitopathy. A Multidisciplinary Approach – Questions and Answers. 2nd, revised version, pp 1-25 Karger; Basel: 2010
   Google Scholar
• Dickinson AJ, Perros P. Controversies in the clinical evaluation of active thyroid associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol (Oxf) 2001;55:283-303
   PubMed Web of Science ®Google Scholar
• Mourits MP, Prummel MF, Wiersinga WM, Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1997;47:9-14; Erratum, Clin Endocrinol (Oxf) 1997;47:632.
   PubMed Web of Science ®Google Scholar
• Uddin JM, Davies PD. Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection. Ophthalmology 2002;109:1183-7
   PubMed Web of Science ®Google Scholar
• Salvi M, Curro N. Management of mild Graves' orbitopathy. In: Wiersinga WM, Kahaly GJ, editors. Graves' Orbitopathy. A Multidisciplinary Approach – Questions and Answers. 2nd, revised version, pp 111-9 Karger; Basel: 2010
   Google Scholar
• Wiersinga WM, Prummel MF, Terwee CB. Effects of Graves' ophthalmopathy on quality of life. J Endocrinol Invest 2004;27:259-64
   PubMed Web of Science ®Google Scholar
• Marcocci C, Kahaly GJ, Krassas GR, Selenium and the course of Graves' orbitopathy. N Engl J Med 2011;364:1920-31
   PubMed Web of Science ®Google Scholar
• Kahaly GJ. Management of moderately severe Graves' orbitopathy. In: Wiersinga WM, Kahaly GJ, editors. Graves' Orbitopathy. A Multidisciplinary Approach – Questions and Answers. 2nd, revised version, pp 120-58 Karger; Basel: 2010
   Google Scholar
• Terwee CB, Prummel MF, Gerding MN, Measuring disease activity to predict therapeutic outcome in Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2005;62:145-55
   PubMed Web of Science ®Google Scholar
• Marcocci C, Bartalena L, Panicucci M. Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves' ophthalmopathy: a comparative study. Clin Endocrinol (Oxf)1987;27:33-42
   PubMed Web of Science ®Google Scholar
• Grossman JM, Gordon R, Ranganath VK, American college of rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010;62:1515-26
   PubMed Web of Science ®Google Scholar
• Marcocci C, Bartalena L, Tanda ML, Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 2001;86:3562-7
   PubMed Web of Science ®Google Scholar
• Macchia PE, Bagattini M, Lupoli G, High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy. J Endocrinol Invest 2001;24:152-8
   PubMed Web of Science ®Google Scholar
• Kahaly GJ, Pitz S, Hommel G, Randomized, single blind trial of intravenous versus oral glucocorticoid monotherapy in Graves' orbitopathy J Clin Endocrinol Metab. 2005;90:5234-40
   Google Scholar
• Aktaran S, Akarsu E, Erbagci I, Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy. Int J Clin Pract 2007;61:45-51
   PubMed Web of Science ®Google Scholar
• Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis. J Clin Endocrinol Metab 2009;94:2708-16
   PubMed Web of Science ®Google Scholar
• Weissel M, Hauff W. Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease. Thyroid 2000;10:521
   PubMed Web of Science ®Google Scholar
• Marino M, Morabito E, Brunetto MR, Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy. Thyroid 2004;14:403-6
   PubMed Web of Science ®Google Scholar
• Lendorf ME, Rasmussen AK, Fledelius HC, Cardiovascular and cerebrovascular events in temporal relationship to intravenous glucocorticoid pulse therapy in patients with severe endocrine ophthalmopathy. Thyroid 2009;19:1431-2
   PubMed Web of Science ®Google Scholar
• Gursoy A, Cesur M, Erdogan MF, New-onset acute heart failure after intravenous glucocorticoid pulse therapy in a patient with Graves' ophthalmopathy. Endocrine 2006;29:513-16
   PubMed Web of Science ®Google Scholar
• Owecki M, Sowinski J. Acute myocardial infarction during high-dose methylprednisolone therapy for Graves' ophthalmopathy. Pharm World Sci 2006;28:73-5
   PubMedGoogle Scholar
• Zang S, Ponto KA, Kahaly GJ. Intravenous glucocorticoid for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 2011;96:320-2
   PubMed Web of Science ®Google Scholar
• Marcocci C, Watt T, Altea MA, Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association. Eur J Endocrinol 2011; Epub ahead of print
   Web of Science ®Google Scholar
• Marino M, Morabito E, Altea MA, Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves. J Endocrinol Invest 2005;28:280-4
   PubMed Web of Science ®Google Scholar
• Salvi M, Vannucchi G, Sbrozzi F, Onset of autoimmune hepatitis during intravenous steroid therapy for thyroid-associated ophthalmopathy in a patient with Hashimoto's thyroiditis: case report. Thyroid 2004;14:631-4
   PubMed Web of Science ®Google Scholar
• Le Moli R, Baldeschi L, Saeed P, Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy. Thyroid 2007;17:357-62
   PubMed Web of Science ®Google Scholar
• Erstad BL. Severe cardiovascular adverse effects in association with acute, high-dose corticosteroid administration. DICP 1989;23:1019-23
   PubMedGoogle Scholar
• Mourits MP, van Kempen-Harteveld ML, Barcia MB, Radiotherapy for Graves' orbitopathy: randomized placebo-controlled study. Lancet 2000;355:1505-9
   PubMed Web of Science ®Google Scholar
• Prummel MF, terwee CB, Gerding MN, A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. J Clin Endocrinol Metab 2004;89:15-20
   PubMed Web of Science ®Google Scholar
• Gorman CA, Garrity JA, Fatourechi V, The aftermath of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology 2002;109:2100-7
   PubMed Web of Science ®Google Scholar
• Prummel MF, Mourits MP, Blank L, Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet 1993;342:949-54
   PubMed Web of Science ®Google Scholar
• Bartalena L, Marcocci C, Chiovato L, Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 1983;56:1139-44
   PubMed Web of Science ®Google Scholar
• Marcocci C, Bartalena L, Bogazzi F, Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Invest 1991;14:853-60
   PubMed Web of Science ®Google Scholar
• Marcocci C, Bartalena L, Rocchi R, Long-term safety of orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab 2003;26:5-16
   Google Scholar
• Wakelkamp IM, Tan H, Saeed P, Orbital irradiation for Graves' ophthalmopathy: is it safe? A long-term follow-up study. Ophthalmology 2004;111:1557-62
   PubMed Web of Science ®Google Scholar
• Bartalena L, Lai A, Compri E, Novel immunomodulating agents for Graves orbitopathy. Ophthal Plast Reconstr Surg 2008;24:251-6
   PubMed Web of Science ®Google Scholar
• Kahaly G, Schrezenmeir J, Krause U, Cyclosporine and prednisone vs. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest 1986;16:415-22
   PubMed Web of Science ®Google Scholar
• Prummel MF, Mourits MP, Berghout L, Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med 1989;321:1353-9
   PubMed Web of Science ®Google Scholar
• Paridaens D, van den Bosch WA, van der Loos TL, The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye 2005;19:1286-9
   PubMed Web of Science ®Google Scholar
• Salvi M, Vannucchi G, Campi I, Treatment of Graves' disease and associated ophthalmopathy with the anti- CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 2007;156:33-40
   PubMed Web of Science ®Google Scholar
• Krassas GE. Childhoood Graves' orbitopathy. In: Wiersinga WM, Kahaly GJ, editors. Graves' Orbitopathy. A Multidisciplinary Approach – Questions and Answers. 2nd, revised version, pp 239-47 Karger; Basel: 2010
   Google Scholar
• Baldeschi L. Rehabilitative surgery. In: Wiersinga WM, Kahaly GJ, editors. Graves' Orbitopathy. A Multidisciplinary Approach – Questions and Answers. 2nd, revised version, pp 167-70 Karger; Basel: 2010
   Google Scholar
• Hart Frantzco RH, Kendall-Taylor P, Crombie A, Early response to intravenous glucocorticoids for severe thyroid-associated ophthalmopathy predicts treatment outcome. J Ocul Pharmacol Ther 2005;21:328-36
   PubMed Web of Science ®Google Scholar
• Wakelkamp IM, Baldeschi L, Saeed P, Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial. Clin Endocrinol (Oxf) 2005;63:323-8
   PubMed Web of Science ®Google Scholar
• Akamizu T, Kaneko H, Noguchi N, Moisture chamber for management of corneal ulcer due to Graves' ophthalmopathy. Thyroid 2000;10:1123-4
   PubMed Web of Science ®Google Scholar
• Baldeschi L. Orbital decompression. In: Wiersinga WM, Kahaly GJ, editors. Graves' Orbitopathy. A Multidisciplinary Approach – Questions and Answers. 2nd, revised version, pp 171-88 Karger; Basel: 2010
   Google Scholar